E7090 selectively inhibits FGFR1–3 and has been found to be effective in patients with cholangiocarcinoma with FGFR2 gene fusions and in patients with gastric cancer with FGFR2 gene amplification or increased expression, but more information is needed for a larger sample size.372. This evidence concerns the gene FGFR2 and gastric cancer.